The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | A Phase I study investigating ruxolitinib and abemaciclib for primary or secondary myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes an ongoing Phase I study which is investigating the novel combination of ruxolitinib and abemaciclib for patients with myeloproliferative neoplasms (MPNs). Dr Bose believes that the combination of a JAK-1/2 and CDK4/6 inhibitor could have synergistic effects in patients with primary or secondary myelofibrosis (MF) who have an inadequate response to ruxolitinib monotherapy. The primary endpoint of this study is to determine the safety and tolerability of this novel combination, and encouraging results are expected. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NS Pharma: Research Funding; Morphosys: Honoraria, Research Funding; Kartos: Honoraria, Research Funding; Sierra Oncology: Honoraria; Karyopharm: Honoraria; Ionis: Research Funding; Incyte: Honoraria, Research Funding; CTI BioPharma: Honoraria, Research Funding; PharmaEssentia: Honoraria; Cogent: Honoraria, Research Funding; Blueprint: Honoraria, Research Funding; BMS: Honoraria, Research Funding; AbbVie: Honoraria; Promedior: Research Funding.
